When was Magnitude Biosciences founded?

Magnitude Biosciences was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Magnitude Biosciences located?

Magnitude Biosciences is headquartered in Durham, United Kingdom.

Which legal entities is Magnitude Biosciences associated with?

Magnitude Biosciences is associated with MAGNITUDE BIOSCIENCES LIMITED.

How many employees does Magnitude Biosciences have?

As of Feb 28, 2025, the latest employee count at Magnitude Biosciences is 21.

Is Magnitude Biosciences a funded company?

Magnitude Biosciences is a funded company, having raised a total of $2.6M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 29, 2018.

How much is Magnitude Biosciences worth?

The latest valuation of Magnitude Biosciences is £***** as of Mar 31, 2025.

When was the latest funding round of Magnitude Biosciences?

Magnitude Biosciences' latest funding was a $***** Grant (prize money) round on May 27, 2025, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. In United Kingdom, the Biopharma Outsourcing sector has seen $34M in funding in 2026 to date.

Where does Magnitude Biosciences rank among its competitors?

Magnitude Biosciences ranks 5th amongst 116 active competitors, of which 11 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Magnitude Biosciences, which secured an undisclosed amount in May, 2025.

Who are the top competitors of Magnitude Biosciences?

Magnitude Biosciences' top competitors include TransCure bioServices, GenOway and Vivo Bio Tech. Among them, Magnitude Biosciences secured the most recent funding round in May, 2025.

Magnitude Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Magnitude Biosciences is a seed company based in Durham (United Kingdom), founded in 2018 by Craig Manning, Boo Virk, Chris Saunter and David Weinkove. It operates as a Provider of early in vivo whole-organism high-throughput phenotypic screening and follow-up assays for drug discovery. Magnitude Biosciences has raised $2.6M in funding from investors like Northstar Ventures, Saker Capital and Europa, with a current valuation of £*****. The company has 116 active competitors, including 11 funded and 21 that have exited. Its top competitors include companies like TransCure bioServices, GenOway and Vivo Bio Tech.

Company Details

Provider of early in vivo whole-organism high-throughput phenotypic screening and follow-up assays for drug discovery. Services include whole organism phenotypic screening of compounds, patient-specific and disease model mutant strains, and small-molecule compound libraries. The company provides quantitative non-invasive assays for health, longevity and mobility outcomes for early drug discovery, as well as tissue-specific assays and mechanism of action elucidation by whole-organism RNA sequencing. Services focus on areas such as aging, neurodegeneration, microbiome, muscle health, reproductive health, gut health and genetic disease modeling, using proprietary automation and imaging technology.

Website: magnitudebiosciences.com
Social
Email ID: *****@magnitudebiosciences.com

Key Metrics

Founded Year

2018

Location

Durham, United Kingdom

Stage

Seed

Total Funding

$2.6M in 6 rounds

Latest Funding Round

Grant (prize money), May 27, 2025, $*****

Post Money Valuation

£***** as on Mar 31, 2025

Investors

Northstar Ventures & 11 more

Ranked

5^th among 116 active competitors

Employee Count

21 as on Feb 28, 2025

Similar Companies

TransCure bioServices & 131 more

View Magnitude Biosciences' full profile

Magnitude Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MAGNITUDE BIOSCIENCES LIMITED CIN: 11579884 , United Kingdom, Active	Sep 19, 2018	-	21 (As on Feb 28, 2025)

Magnitude Biosciences has raised a total funding of $2.6M over 6 rounds. Its first funding round was on Nov 29, 2018. Its latest funding round was a Grant (prize money) round on May 27, 2025 for $*****. 1 investor participated in its latest round. Magnitude Biosciences has 9 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Magnitude Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 27, 2025	7872083	Grant (prize money)	1960653	2734957	8196547	4801394
Mar 31, 2025	3282428	Seed	7709609	5143799	7676722	Maven Capital Partners & 1 more
Oct 27, 2022	7177350	Seed	8194436	4813527	Europa & 2 more	9962072

Access funding benchmarks and valuations. Sign up today!

View details of Magnitude Biosciences's funding rounds and investors

The founders of Magnitude Biosciences are Craig Manning, Boo Virk, Chris Saunter and David Weinkove.

Here are the details of Magnitude Biosciences' key team members:

Craig Manning: Former Co-Founder & Director of Magnitude Biosciences.
Contact Info: 1 email address
Boo Virk: Former Co-Founder of Magnitude Biosciences.
Contact Info: 1 email address
Chris Saunter: Co-Founder & Director of Magnitude Biosciences. They serve on the board of 1 company.
Contact Info: 1 email address
David Weinkove: Co-Founder & Chief Scientific Officer of Magnitude Biosciences. They are also an angel investor in 1 startup.

Magnitude Biosciences' Board of Directors

Magnitude Biosciences's board has 4 active members. Sally Christina Waterman, Fozia Saleem and Chris Saunter are part of team and Derek Wilson Mcferran is independent board member.

Here is the list of Magnitude Biosciences' board of directors:

Name	Type	Representing	Status	Duration
kruoesq	Team	-	Past	5y 7m
tvtgmpp	Team	-	Past	2y 7m
yszmrgw	Team	-	Current	5y 2m
nrzpxfw	Team	-	Current	8y 3m
Chris Saunter	Investor	-	Current	7y 9m
oowfrpq	Investor	-	Past	8y 6m
Derek Wilson Mcferran	Independent board member	-	Current	0y 11m
wtfdrin	Independent board member	-	Past	1y 6m

View details of Magnitude Biosciences's Founder profiles and Board Members

Magnitude Biosciences' employee count trend

Magnitude Biosciences has 21 employees as of Feb 25. Here is Magnitude Biosciences's employee count trend over the years:

Employee count trend for Magnitude Biosciences

Uncover Magnitude Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Magnitude Biosciences include TransCure bioServices, GenOway and Vivo Bio Tech. Here is the list of Top 10 competitors of Magnitude Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	TransCure bioServices 2012, Archamps (France), Series B	Developer of humanized animal models for preclinical studies	$3.58M	Financiere Arbevel, Savoie Mont Blanc Angels ... & 5 others	59/100
2nd	GenOway 1999, Lyon (France), Public	Provider of transgenic rodent models and customized cell lines for preclinical development	$11.6M	Eurostars, Siparex & 7 others	58/100
3rd	Vivo Bio Tech 2004, Hyderabad (India), Public	CRO providing drug development, discovery and biologic research services	-	BIRAC	52/100
4th	InVivo Biosystems 2019, Eugene (United States), Series A	Provider of animal models for in-vivo analytical services	$8.16M	Rogue Venture Partners, Launch Oregon & 6 others	46/100
5th	Magnitude Biosciences 2018, Durham (United Kingdom), Seed	Provider of early in vivo whole-organism high-throughput phenotypic screening and follow-up assays for drug discovery	$2.6M	British Business Bank, Ukri & 10 others	46/100
6th	Alpha Genesis 2003, Yemassee (United States), Series B	Preclinical research services specializing in nonhuman primate models for therapy development	$12.5M	-	45/100
7th	Explora BioLabs 2004, San Diego (United States), Acquired	Provider of discovery pharmacology and vivarium services for biotechnology and pharmaceutical clients	-	Milk Street Ventures, Aspect Investors & 2 others	42/100
8th	Neurofit 1996, Illkirch Graffenstaden (France), Acquired	Animal models of neurological and psychiatric disorders for drug discovery	-	-	39/100
9th	Fibrofind United Kingdom, Acquired	Provider of preclinical drug development research solutions for fibrotic diseases	-	-	39/100
10th	Noble Life Sciences 2010, Woodbine (United States), Seed	Preclinical contract research organization offering standard GLP and non-GLP services	$335K	1776, TEDCO & 3 others	37/100